.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Hashimoto’s thyroiditis (HT) and rheumatoid arthritis (RA) often coexist, posing a diagnostic challenge for clinicians in India. A recent systems biology study published in Aging Male explores the shared molecular signatures between these two autoimmune conditions. By analyzing public datasets, researchers identified 196 common differentially expressed genes and 10 central hub genes. Consequently, this research suggests that Hashimoto's and Rheumatoid Arthritis share deeply linked immune-mediated pathways.
The study highlights that aberrant immune activation and the loss of self-tolerance drive the comorbidity of these disorders. Researchers performed functional enrichment analysis to link these genes to specific inflammatory biological processes. Furthermore, single-sample gene set enrichment analysis indicated that activated B cells play a central role in disease development. Because these cells contribute significantly to both conditions, they represent a critical area for further clinical investigation.
The team constructed a detailed regulatory network to pinpoint key modulators of these shared genes. Through computational drug target prediction, the study identified CD2, CTLA4, and CD27 as promising therapeutic targets. Although these results require experimental validation, they provide a strong theoretical basis for precision medicine. Moreover, early screening for thyroid dysfunction in patients with rheumatoid arthritis may improve overall outcomes. Therefore, identifying these hub genes marks a significant step toward targeted therapies.
Studies show that approximately 30% of rheumatoid arthritis patients may also have Hashimoto's thyroiditis, emphasizing the need for regular screening.
Current research suggests that activated B cells are central to the pathogenesis and inflammatory response in both Hashimoto's and Rheumatoid Arthritis.
The study identifies CD2, CTLA4, and CD27 as potential molecular targets for developing precision therapeutic strategies in the future.
Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A systems biology study identifies 196 shared genes and immune pathways between Hashimoto's and Rheumatoid Arthritis, revealing potential therapeutic target...
5 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
